Market Overview

Seattle Genetics Confirms FDA Orphan Drug Status for ADCETRIS

Share:
Related SGEN
Jefferies: 10 Buyout Targets To Own During The M&A Boom
Kinder Morgan, Seattle Genetics And Others Insiders Have Been Buying
Seattle Genetics Posts Narrower-than-Expected Loss in Q1 - Analyst Blog (Zacks)

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology Company, are conducting the ALCANZA trial, a phase III clinical trial of ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS is not approved for the treatment of CTCL.

Posted-In: News FDA

 

Related Articles (SGEN)

Around the Web, We're Loving...